((自动化翻译由路透提供，请见免责声明 )) (全程补充交易背景)
路透12月9日 - 抗皱注射剂生产商Revance Therapeutics 和私人控股公司Crown Laboratories周一表示，两家公司已同意以每股3.10美元的 价格收购Revance Therapeutics ，而不是之前商定的每股6.66美元。
Revance 的股价在盘前交易中下跌了 20.4%。
两家公司预计交易将于 2025 年第一季度完成。
Revance在9月份表示，它收到了一份违反Teoxane皮肤填充剂独家经销协议的通知，因此降低了收购报价。这导致 Crown 和 Revance 延长了 8 月份首次宣布的交易完成日期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.